Urologic Oncology: Seminars and Original Investigations
Volume 24, Issue 2 , Pages 141-151 , March 2006

Small molecule, oligonucleotide-based telomerase template inhibition in combination with cytolytic therapy in an in vitro androgen-independent prostate cancer model

  • Benjamin K. Canales, M.D., M.P.H.

      Affiliations

    • Department of Urology, University of Minnesota, Minneapolis, MN 55455, USA
    • ,
  • Yingming Li, M.D.

      Affiliations

    • Department of Urology, University of Minnesota, Minneapolis, MN 55455, USA
    • ,
  • Melissa G. Thompson, B.A.

      Affiliations

    • Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    • ,
  • Joseph M. Gleason, M.S.

      Affiliations

    • Department of Urology, University of Minnesota, Minneapolis, MN 55455, USA
    • ,
  • Zhi Chen, Ph.D.

      Affiliations

    • Department of Pharmacology and Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    • ,
  • Bahaa Malaeb, M.D.

      Affiliations

    • Department of Urology, University of Minnesota, Minneapolis, MN 55455, USA
    • ,
  • David R. Corey, Ph.D.

      Affiliations

    • Department of Pharmacology and Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    • ,
  • Brittney-Shea Herbert, Ph.D.

      Affiliations

    • Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    • Indiana University Cancer Center and Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    • ,
  • Jerry W. Shay, Ph.D.

      Affiliations

    • Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    • ,
  • Kenneth S. Koeneman, M.D.

      Affiliations

    • Department of Urology, University of Minnesota, Minneapolis, MN 55455, USA
    • Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    • Center for Prostate Cancer, University of Minnesota, Minneapolis, MN 55455, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-612-626-0964.

References 

  1. Hayfick L , Moorhead PS . The limited in vitro lifetime of human diploid cell strains . Exp Cell Res . 1961;25:585–621
  2. Watson JD . Origin of concatemeric T7 DNA . Nat New Biol . 1972;239:197–201
  3. Olovnikov AM . A theory of marginotomy (The incomplete copying of template margin in enzymatic synthesis of polynucleotides and the biological significance of the phenomenon) . J Theor Biol . 1973;41:181–190
  4. Huffman KE , Levene SD , Tesmer VM , et al.   Telomere shortening is proportional to the size of the G-rich telomeric 3′-overhang . J Biol Chem . 2000;275:19719–19722
  5. Harley CB , Futcher AB , Greider CW . Telomeres shorten during aging of human fibroblasts . Nature . 1990;345:458–460
  6. Hastie ND , Dempster M , Dunlop MG , et al.   Telomere reduction in human colorectal carcinoma and with aging . Nature . 1990;346:866–868
  7. Counter CM , Hirte HW , Bachetti S , et al.   Telomerase activity in human ovarian carcinoma . Proc Natl Acad Sci USA . 1994;91:2900–2904
  8. Moyzis RK , Buckingham JD , Cram LS , et al.   A highly conserved repetitive DNA sequence, (TTAGGG)n, present at telomeres of human chromosomes . Proc Natl Acad Sci USA . 1988;85:6622–6626
  9. Makarov VL , Hirose Y , Langmore JP . Long G tails at both ends of human chromosomes suggest a C strand degradation mechanism for telomere shortening . Cell . 1997;88:657–666
  10. Van Steensel B , Smogorzewska A , de Lange T . TRF2 protects human telomeres from end-to-end fusions . Cell . 1998;92:401–413
  11. Griffith JD , Comeau L , Rosenfield S , et al.   Mammalian telomeres end in a large duplex loop . Cell . 1999;97:503–514
  12. Smogorzewska A , van Steensel B , Bianchi A , et al.   Control of human telomere length by TRF1 and TRF2 . Mol Cell Biol . 2000;20:1659–1668
  13. Sherr CJ , McCormick F . The RB and p53 pathways in cancer . Cancer Cell . 2002;2:103–112
  14. Smogorzewska A , de Lange T . Different telomere damage signaling pathways in human and mouse cells . EMBO J . 2002;21:4338–4348
  15. Shay JW , Wright WE . Telomerase (A target for cancer therapeutics) . Cancer Cell . 2002;2:257–265
  16. Cooke HJ , Smith BA . Variability at the telomeres of the human X/Y pseudoautosomal region . Cold Spring Harb Symp Quant Biol . 1986;51:213–219
  17. Harley CB . Telomere loss (Mitotic clock or genetic time bomb?) . Mutat Res . 1991;256:271–282
  18. Kim NW , Pietyszek MA , Prowse KR , et al.   Specific association of human telomerase activity with immortal cells and cancer . Science . 1994;266:2011–2020
  19. Shay JW , Bacchetti S . A survey of telomerase activity in human cancer . Eur J Cancer . 1997;5:787–791
  20. Feng J , Funk WD , Wang S-S , et al.   The RNA component of human telomerase . Science . 1995;269:1236–1241
  21. Nakamura TM , Morin GB , Chapman KB , et al.   Telomerase catalytic subunit homologs from fission yeast and human . Science . 1997;277:955–959
  22. Meyerson M , Counter CM , Eaton EN , et al.   hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization . Cell . 1997;90:785–795
  23. Harrington L , McPhail T , Mar V , et al.   Human telomerase contains evolutionarily conserved catalytic and structural subunits . Genes Dev . 1997;11:3109–3115
  24. Bodnar AG , Ouellette M , Frolkis M , et al.   Extension of life-span by introduction of telomerase into normal human cells . Science . 1998;279:349–352
  25. Morales CP , Holt SE , Ouellette M , et al.   Absence of cancer-associated changes in human fibroblasts immortalized with telomerase . Nat Genet . 1999;21:115–118
  26. Harley CB . Telomerase is not an oncogene . Oncogene . 2002;21:494–502
  27. Hahn WC , Counter CM , Lundberg AS , et al.   Creation of human tumour cells with defined genetic elements . Nature . 1999;400:464–468
  28. Herbert BS , Pitts AE , Baker SI , et al.   Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death . Proc Natl Acad Sci USA . 1999;96:14276–14281
  29. Zhang XL , Mar V , Zhou W , et al.   Telomere shortening and apoptosis in telomerase-inhibited human tumour cells . Genes Dev . 1999;13:2388–2399
  30. Nilsson P , Mehle C , Remes K , et al.   Telomerase activity in vivo in human malignant hematopoietic cells . Oncogene . 1994;9:3043–3048
  31. Shay JW , Zou Y , Hiyama E , et al.   Telomerase and cancer . Hum Mol Genet . 2001;10:677–685
  32. Langford LA , Piatyszek MA , Xu R , et al.   Telomerase activity in human brain tumors . Lancet . 1995;346:1267–1268
  33. de Lange T . Activation of telomerase in human tumor . Proc Natl Acad Sci USA . 1994;91:2882–2885
  34. Lin Y , Uemura H , Fujinami K , et al.   Telomerase activity in primary prostate cancer . J Urol . 1997;157:1161–1165
  35. Lin Y , Uemura H , Fujinami K , et al.   Detection of telomerase activity in prostate needle-biopsy samples . Prostate . 1998;36:121–128
  36. Zhang W , Kapusta LR , Slingerland JM , et al.   Telomerase activity in prostate cancer, prostatic intraepithelial neoplasia, and benign prostatic epithelium . Cancer Res . 1998;58:619–622
  37. Kallakury BV , Bhaskar VS , Brien TP , et al.   Telomerase activity in human benign prostate tissue and prostatic adenocarcinomas . Diagn Mol Pathol . 1997;6:192–198
  38. Takahashi C , Miyagawa I , Kumano S , et al.   Detection of telomerase activity in prostate cancer by needle biopsy . Eur Urol . 1997;32:494–498
  39. Sommerfeld HJ , Meeker AK , Piatyszek MA , et al.   Telomerase activity (A prevalent marker of malignant human prostate tissue) . Cancer Res . 1996;56:218–222
  40. Wullich B , Rohde V , Oehlenschlager B , et al.   Focal intratumoral heterogeneity for telomerase activity in human prostate cancer . J Urol . 1999;161:1997–2001
  41. Koenenman K , Pan CX , Jin JK , et al.   Telomerase activity, telomere length and DNA ploidy in prostatic intraepithelial neoplasia (PIN) . J Urol . 1998;160:1533–1539
  42. Damm K , Hemmann U , Garin-Chesa P , et al.   A highly selective telomerase inhibitor limiting human cancer cell proliferation . EMBO J . 2001;20:6958–6968
  43. Shay JW , Wright WE . Mechanism-based combination telomerase inhibition therapy . Cancer Cell . 2005;7:1–2
  44. Forsyth NR , Wright WE , Shay JW . Telomerase and differentiation in multicellular organisms (Turn it off, turn it on, and turn it off again) . Differentiation . 2002;69:188–197
  45. Mahmud N , Devine SM , Weller KP , et al.   The relative quiescence of hematopoietic stem cells in nonhuman primates . Blood . 2001;97:3061–3068
  46. Kim MM , Rivera MA , Botchkina IL , et al.   A low threshold level of expression of mutant-template telomerase RNA inhibits human tumor cell proliferation . Proc Natl Acad Sci USA . 2001;98:7982–7987
  47. Koga S , Hirohata S , Kondo Y , et al.   FADD gene therapy using the human telomerase catalytic subunit (hTERT) gene promoter to restrict induction of apoptosis to tumors in vitro and in vivo . Anticancer Res . 2001;21:1937–1943
  48. Gu J , Andreff M , Roth JA , et al.   hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity . Gene Ther . 2002;9:30–37
  49. Vonderheide RH . Telomerase as a universal tumor-associated antigen for cancer immunotherapy . Oncogene . 2002;21:674–679
  50. Naasani I , Oh-Hashi F , Oh-Hara T , et al.   Blocking telomerase by dietary polyphenols is a major mechanism for limiting the growth of human cancer cells in vitro and in vivo . Cancer Res . 2003;63:824–830
  51. Sun D , Thompson B , Cathers BE , et al.   Inhibition of human telomerase by a G-quadruplex-interactive compound . J Med Chem . 1997;40:2113–2116
  52. Strahl C , Blackburn EH . Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines . Mol Cell Biol . 1996;16:53–65
  53. Yokoyama Y , Takahashi T , Shinohara A , et al.   Attenuation of telomerase activity by a hammerhead ribozyme targeting the template region of telomerase RNA in endometrial carcinoma cells . Cancer Res . 1998;58:5406–5410
  54. Corey DR . Telomerase inhibition, oligonucleotides, and clinical trials . Oncogene . 2002;21:631–637
  55. Herbert BS , Pongracz K , Shay JW , et al.   Oligonucleotide N3′-P5′ phosphoramidates as efficient telomerase inhibitors . Oncogene . 2002;21:638–642
  56. Baker BF , Monia BP . Novel mechanisms for antisense-mediated regulation of gene expression . Biochim Biophys Acta . 1999;1489:3–18
  57. Jansen B , Zangemeister-Wittke U . Antisense therapy for cancer (the time of truth) . Lancet Oncol . 2002;3:672–682
  58. Corey DR . Telomerase (An unusual target for cytotoxic agents) . Chem Res Toxicol . 2000;13:957–960
  59. Geary RS , Yu RZ , Levin AA . Drug properties of second-generation antisense oligonucleotides (How do they measure up to their predecessors?) . Curr Opin Investig Drugs . 2001;2:1444–1449
  60. Chen Z , Koeneman K , Corey DR . Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells . Cancer Res . 2003;63:5917–5925
  61. Inoue H , Hayase Y , Imura A , et al.   Synthesis and hybridization studies on two complementary nona(2′-O-methyl)ribonucleotides . Nucleic Acids Res . 1987;15:6131–6148
  62. Monia BP , Lesnik EA , Gonzalez C , et al.   Evaluation of 2′ modified oligonucleotides containing deoxy gaps as antisense inhibitors of gene expression . J Biol Chem . 1993;268:14514–14522
  63. McKay RA , Miraglia LJ , Cummins LL , et al.   Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression . J Biol Chem . 1999;274:1715–1722
  64. Baker BF , Lot SS , Condon TP , et al.   2′-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells . J Biol Chem . 1997;272:11994–12000
  65. Henry SP , Stecker K , Brooks D , et al.   Chemically modified oligonucleotides exhibit decreased immune stimulation in mice . J Pharmacol Exp Ther . 2000;292:468–479
  66. McCaffrey JA , Hilton S , Mazumdar M , et al.   Phase II trial of docetaxel in-patients with advanced or metastatic transitional-cell carcinoma . J Clin Oncol . 1997;15:1853–1857
  67. Petrylak DP , Tangen CM , Hussain MH , et al.   Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer . N Engl J Med . 2004;351:1513–1520
  68. Tannock IF , de Wit R , Berry WR , et al.   Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer . N Engl J Med . 2004;351:1502–1512
  69. Chung LW , Hsieh CL , Law A , et al.   New targets for therapy in prostate cancer (Modulation of stromal-epithelial interactions) . Urology . 2003;62:44–54
  70. Kanamaru H , Yoshida O . Assessment of in vitro lymphokine activated killer (LAK) cell activity against renal cancer cell lines and its suppression by serum factor using crystal violet assay . Urol Res . 1989;17:259–264
  71. Ouellette MM , Liao M , Herbert B , et al.   Subsenescent telomere lengths in fibroblasts immortalized by limiting amounts of telomerase . J Biol Chem . 2000;275:10072–10076
  72. Li Y , Okegawa T , Lombardi DP , et al.   Enhanced transgene expression in androgen independent prostate cancer gene therapy by taxane chemotherapeutic agents . J Urol . 2002;167:339–346
  73. Zhang X , Multani AS , Zhou JH , et al.   Adenoviral-mediated retinoblastoma 94 produces rapid telomere erosion, chromosomal crisis, and caspase-dependent apoptosis in bladder cancer and immortalized human urothelial cells but not in normal urothelial cells . Cancer Res . 2003;63:760–765
  74. Li S , Crothers J , Haqq CM , et al.   Cellular and gene expression responses involved in the rapid growth inhibition of human cancer cells by RNA interference-mediated depletion of telomerase RNA . J Biol Chem . 2005;280:23709–23717

☆ This work was supported by a New Award Idea, Department of Defense, CDMRP, DAMD 17-01-1-0107 “Targeting Osteoblastic Bone Metastasis with a Novel Site Restricted Gene Therapy” and Department of Defense, CDMRP, DAMD17-02-1-0148 “Targeting Orthotopic and Osseous Prostate Cancer Xenografts with Selective, Systemic Telomerase Inhibition” (K.S.K.), and a subcontract to DOD Consortium Award, DAMD17-03-2-0033 to Emory University (P.I. Jonathan Simmons).

 Isis Corporation and Geron Corporation provided small molecule, oligonucleotide-based telomerase template inhibitors used in this study.

PII: S1078-1439(05)00264-4

doi: 10.1016/j.urolonc.2005.11.003

Urologic Oncology: Seminars and Original Investigations
Volume 24, Issue 2 , Pages 141-151 , March 2006

Article Tools

* Image Usage & Resolution